Ouch. Jury returns $ 1.67 billion verdict against Abbott (patent infringement vs J&J) - A U.S. federal jury returned a $1.67 billion verdict against Abbott Laboratories in a patent suit brought by …
Today’s Top Three in Pharma 062909
I think it's going to be more than 3 today...! Does Lantus (Sanofi drug for diabetes) increase cancer risk? Takeda's alogliptin (new diabetes treatment) - FDA says, more info please. European …
Today’s Top Three in Pharma 060409
OK, so it's a "baker's three" (8) today. Makes up for yesterday's zero...! Patent-holder urges FDA to NOT approve prasugrel (from Lilly/Daiichi Sankyo). Novartis getting cold feet at the Alcon …
Today’s Top (8) in Pharma 050709
This will probably be the last Top Three post for about a week or so, as I head out to Chicago for the SPBT (Society of Pharmaceutical and Biotech Trainers) conference. And there's a bit of backlog …
Today’s Top Three in Pharma 042309
FDA extends review of AstraZeneca/BMS experimental diabetes drug Onglyza. Teva blocked from launching generic form of Lilly's Evista; also rumored to be eyeballing a purchase of …
Today’s Top Three in Pharma 041609
GSK and Pfizer join forces to create a new company focused on HIV. I really like the idea here - I think highly-focused companies can be much more nimble and effective. Dendreon finally gets some …